Pricing Log in Create free account

Aceragen, Inc. (ACGN) vs TScan Therapeutics, Inc. (TCRX)

Aceragen, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Aceragen, Inc. and TScan Therapeutics, Inc. are of similar size ($17.1M and $16.2M). Aceragen, Inc. grew revenue faster over the last twelve months: 1,226.3% against 2.15%. Aceragen, Inc. has the higher net margin (−467.5% vs −1,655.4%) and the higher return on invested capital (−135.4% vs −4,588.2%). Across the 18 metrics below, Aceragen, Inc. leads on 11 and TScan Therapeutics, Inc. on 7.

Valuation

Metric ACGN TCRX Biotechnology median
P/E n/m n/m 8.50
P/S 1.52 4.20 9.71
P/B 0.83 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.32 0.64
EV/Sales 4.09 (5.27) 9.21
Earnings yield (181.40%) (395.65%) (33.15%)
Free cash flow yield (250.88%) (396.18%) (25.50%)

Profitability

Metric ACGN TCRX Biotechnology median
Gross margin 83.46% 100.00% 65.16%
Operating margin (503.92%) (1,695.15%) 0.00%
Net margin (467.53%) (1,655.35%) 0.00%
Free cash flow margin (339.17%) (1,665.18%) 0.00%
Return on equity (169.66%) (95.80%) (56.36%)
Return on assets (75.58%) (50.09%) (48.04%)
Return on invested capital (135.35%) (4,588.23%) 0.00%

Growth

Metric ACGN TCRX Biotechnology median
Revenue growth (TTM) 1,226.28% 2.15% 6.02%
EPS growth (last fiscal year) (121.58%) 12.28% 30.26%
Revenue growth, 5-year CAGR 81.19% 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACGN TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 0.32 3.37 4.72
Net debt to EBITDA 0.43 0.90 0.96

Dividend

Metric ACGN TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACGN TCRX Biotechnology median
Market cap 17.15m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack